Cardiac non-human leukocyte antigen identification

Techniques and troubles

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Historically efforts have focused on the human leukocyte antigen (HLA) as the major cause for acute and chronic rejection following cardiac transplantation. However, rising evidence indicates that non-HLA antibodies can be both primary initiators and modifiers of antibody-mediated rejection (AMR) and cardiac allograft vasculopathy (CAV). The purpose of this review is to assess currently available technologies for non-HLA identification and leveraging such responses toward antibody quantification. Several techniques have been used to identify antigenic determinants of recipient graft-specific non-HLA humoral immune responses, but each comes with its own set of benefits and caveats. Improving our ability to detect non-HLA humoral immune response will aid in our understanding of the underlying antigenic determinants of AMR and CAV, as well as improve patient outcomes.

Original languageEnglish (US)
JournalFrontiers in Immunology
Volume8
Issue numberOCT
DOIs
StatePublished - Oct 18 2017

Fingerprint

HLA Antigens
Humoral Immunity
Allografts
Antibodies
Epitopes
Heart Transplantation
Antibody Formation
Technology
Transplants

Keywords

  • Antigen identification
  • Heart transplantation
  • Immunoproteomics
  • Non-human leukocyte antigen antibody
  • Proteomics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Cardiac non-human leukocyte antigen identification : Techniques and troubles. / Gates, Katherine V.; Pereira, Naveen Luke; Griffiths, Leigh.

In: Frontiers in Immunology, Vol. 8, No. OCT, 18.10.2017.

Research output: Contribution to journalReview article

@article{1d610f178c44431791252cf391498ba2,
title = "Cardiac non-human leukocyte antigen identification: Techniques and troubles",
abstract = "Historically efforts have focused on the human leukocyte antigen (HLA) as the major cause for acute and chronic rejection following cardiac transplantation. However, rising evidence indicates that non-HLA antibodies can be both primary initiators and modifiers of antibody-mediated rejection (AMR) and cardiac allograft vasculopathy (CAV). The purpose of this review is to assess currently available technologies for non-HLA identification and leveraging such responses toward antibody quantification. Several techniques have been used to identify antigenic determinants of recipient graft-specific non-HLA humoral immune responses, but each comes with its own set of benefits and caveats. Improving our ability to detect non-HLA humoral immune response will aid in our understanding of the underlying antigenic determinants of AMR and CAV, as well as improve patient outcomes.",
keywords = "Antigen identification, Heart transplantation, Immunoproteomics, Non-human leukocyte antigen antibody, Proteomics",
author = "Gates, {Katherine V.} and Pereira, {Naveen Luke} and Leigh Griffiths",
year = "2017",
month = "10",
day = "18",
doi = "10.3389/fimmu.2017.01332",
language = "English (US)",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TY - JOUR

T1 - Cardiac non-human leukocyte antigen identification

T2 - Techniques and troubles

AU - Gates, Katherine V.

AU - Pereira, Naveen Luke

AU - Griffiths, Leigh

PY - 2017/10/18

Y1 - 2017/10/18

N2 - Historically efforts have focused on the human leukocyte antigen (HLA) as the major cause for acute and chronic rejection following cardiac transplantation. However, rising evidence indicates that non-HLA antibodies can be both primary initiators and modifiers of antibody-mediated rejection (AMR) and cardiac allograft vasculopathy (CAV). The purpose of this review is to assess currently available technologies for non-HLA identification and leveraging such responses toward antibody quantification. Several techniques have been used to identify antigenic determinants of recipient graft-specific non-HLA humoral immune responses, but each comes with its own set of benefits and caveats. Improving our ability to detect non-HLA humoral immune response will aid in our understanding of the underlying antigenic determinants of AMR and CAV, as well as improve patient outcomes.

AB - Historically efforts have focused on the human leukocyte antigen (HLA) as the major cause for acute and chronic rejection following cardiac transplantation. However, rising evidence indicates that non-HLA antibodies can be both primary initiators and modifiers of antibody-mediated rejection (AMR) and cardiac allograft vasculopathy (CAV). The purpose of this review is to assess currently available technologies for non-HLA identification and leveraging such responses toward antibody quantification. Several techniques have been used to identify antigenic determinants of recipient graft-specific non-HLA humoral immune responses, but each comes with its own set of benefits and caveats. Improving our ability to detect non-HLA humoral immune response will aid in our understanding of the underlying antigenic determinants of AMR and CAV, as well as improve patient outcomes.

KW - Antigen identification

KW - Heart transplantation

KW - Immunoproteomics

KW - Non-human leukocyte antigen antibody

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85031736218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031736218&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.01332

DO - 10.3389/fimmu.2017.01332

M3 - Review article

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - OCT

ER -